Results 141 to 150 of about 3,969,797 (240)

Lab on an end: Micromanipulation using the acoustohydrodynamic pillar array as an end effector. [PDF]

Proc Natl Acad Sci U S A
Chen Z, Bai C, Liu F, Huang Q, Fukuda T, Arai T, Liu X.   +6 more
europepmc   +1 more source

Switch controllers of an n-link revolute manipulator with a prismatic end-effector for landmark navigation. [PDF]

PeerJ Comput Sci, 2022
Chand R, Chand RP, Kumar SA.
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

End-Effector Robot-Assisted Gait Training in Quadruple Amputees: Two Case Reports. [PDF]

Ann Rehabil Med
Kim Y, Oh Y, Shin S, Oh D, Cho SI, Jeong J, Yoo J.   +6 more
europepmc   +1 more source

A-SEE: Active-Sensing End-effector Enabled Probe Self-Normal-Positioning for Robotic Ultrasound Imaging Applications. [PDF]

IEEE Robot Autom Lett, 2022
Ma X, Kuo WY, Yang K, Rahaman A, Zhang HK.   +4 more
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Feasibility study of the assessment of upper limb function in children with Unilateral Cerebral Palsy using an end-effector robotic device. [PDF]

J Neuroeng Rehabil
Barzacchi V, Beani E, Filogna S, Sgherri G, Menici V, Marsanich G, Mazzoleni S, Cioni G, Sgandurra G.   +8 more
europepmc   +1 more source

A Constant-Force End-Effector With Online Force Adjustment for Robotic Ultrasonography. [PDF]

IEEE Robot Autom Lett, 2021
Bao X, Wang S, Housden R, Hajnal J, Rhode K.   +4 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

The Effects of Clinical Applications of Robot-Assisted Therapy Methods: End-Effector, Fixed Exoskeleton, and Wearable Exoskeleton on Functional Activities in Stroke Patients. [PDF]

Life (Basel)
Lee JH.
europepmc   +1 more source